一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>943609-66-3

943609-66-3

中文名稱 維多珠單抗
英文名稱 Vedolizumab
CAS 943609-66-3
更新日期 2026/06/01 09:39:06
943609-66-3 結(jié)構(gòu)式 943609-66-3 結(jié)構(gòu)式

基本信息

中文別名
維多珠單抗
維多組單抗
VEDOLIZUMAB ( 維多組單抗 )
英文別名
Vedolizumab
Vedolizumab USP/EP/BP
所屬類別
原料藥:其它消化系統(tǒng)用藥

物理化學(xué)性質(zhì)

儲存條件Store at -80°C
溶解度溶于二甲基亞砜
形態(tài)Solid
顏色White to off-white

常見問題列表

單克隆抗體

維多珠單抗(vedolizumab)是一種全人源化單克隆抗體,特異性拮抗α4β7整合素,抑制α4β7整合素對腸道黏膜細(xì)胞粘附分子MAdCAM-1的結(jié)合。

2014年5月,美國FDA批準(zhǔn)維多珠單抗上市,用于對常規(guī)療法或一種TNF-α拮抗劑不耐受、或不再響應(yīng)、或響應(yīng)不足的中度至重度活動性潰瘍性結(jié)腸炎(UC)或克羅恩病(Crohn's disease,CD)成人患者的治療。

生物活性
Vedolizumab是一種靶向α4β7整聯(lián)蛋白 (integrin) 的人源化單克隆抗體,用于潰瘍性結(jié)腸炎和克羅恩病的相關(guān)研究。
靶點(diǎn)

Integrin

體外研究

Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC 50 =0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC 50 =0.02-0.06 g/mL) and fibronectin (IC 50 =0.02 g/mL), but not vascular cell adhesion molecule 1.

體內(nèi)研究

Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups.

維多珠單抗價格(試劑級)
報(bào)價日期產(chǎn)品編號產(chǎn)品名稱CAS號包裝價格
2025/12/22HY-P9911A維多珠單抗
Vedolizumab (anti-α4β7-integrin)
943609-66-31 mg1700元
2025/12/22HY-P9911A維多珠單抗
Vedolizumab (anti-α4β7-integrin)
943609-66-35 mg4500元
2025/12/22HY-P9911維多珠單抗
Vedolizumab
943609-66-31mg1700元
"943609-66-3" 相關(guān)產(chǎn)品信息
9002-68-0 875356-43-7 945721-28-8 242138-07-4 923950-08-7 1018448-65-1 347396-82-1 188039-54-5 189261-10-7 219685-50-4 339186-68-4 476181-74-5 862111-32-8 143653-53-6 745013-59-6 1537032-82-8 828933-51-3 356547-88-1
射洪县| 浠水县| 蒙山县| 宜州市| 会东县| 台山市| 萍乡市| 灌南县| 安阳县| 乌恰县| 克山县| 庆阳市| 望奎县| 常熟市| 习水县| 萨迦县| 讷河市| 鹤庆县| 合川市| 新宁县| 福海县| 定日县| 乌拉特前旗| 关岭| 治多县| 翼城县| 莆田市| 福建省| 汽车| 昭通市| 广德县| 灵武市| 清流县| 出国| 甘洛县| 山阴县| 万盛区| 法库县| 柘城县| 西乡县| 皮山县|